FI972793A0 - Nebivololin käyttö antiaterogeenisenä aineena - Google Patents

Nebivololin käyttö antiaterogeenisenä aineena

Info

Publication number
FI972793A0
FI972793A0 FI972793A FI972793A FI972793A0 FI 972793 A0 FI972793 A0 FI 972793A0 FI 972793 A FI972793 A FI 972793A FI 972793 A FI972793 A FI 972793A FI 972793 A0 FI972793 A0 FI 972793A0
Authority
FI
Finland
Prior art keywords
nebivolol
alpha
antiatherogenic
agent
antiatherogenic agent
Prior art date
Application number
FI972793A
Other languages
English (en)
Swedish (sv)
Other versions
FI972793L (fi
FI118884B (fi
Inventor
Chaffoy De Courcelles Didie De
Anne Simone Josephine Lesage
Josepha Eduarda Maria F Leysen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI972793L publication Critical patent/FI972793L/fi
Publication of FI972793A0 publication Critical patent/FI972793A0/fi
Application granted granted Critical
Publication of FI118884B publication Critical patent/FI118884B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
FI972793A 1994-12-28 1997-06-27 Nebivololin käyttö antiaterogeenisenä aineena FI118884B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
EP94203775 1994-12-28
EP9505174 1995-12-21
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Publications (3)

Publication Number Publication Date
FI972793L FI972793L (fi) 1997-06-27
FI972793A0 true FI972793A0 (fi) 1997-06-27
FI118884B FI118884B (fi) 2008-04-30

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972793A FI118884B (fi) 1994-12-28 1997-06-27 Nebivololin käyttö antiaterogeenisenä aineena

Country Status (20)

Country Link
US (2) US5874461A (fi)
EP (1) EP0801564B1 (fi)
JP (1) JPH10511655A (fi)
KR (1) KR100264348B1 (fi)
CN (1) CN1167418C (fi)
AT (1) ATE214924T1 (fi)
AU (1) AU700364B2 (fi)
CA (1) CA2207333C (fi)
CZ (1) CZ287513B6 (fi)
DE (1) DE69526120T2 (fi)
DK (1) DK0801564T3 (fi)
ES (1) ES2176354T3 (fi)
FI (1) FI118884B (fi)
HU (1) HU226208B1 (fi)
NO (1) NO315687B1 (fi)
NZ (1) NZ298074A (fi)
PT (1) PT801564E (fi)
SI (1) SI0801564T1 (fi)
SK (1) SK282144B6 (fi)
WO (1) WO1996019987A1 (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226208B1 (en) * 1994-12-28 2008-06-30 Janssen Pharmaceutica Nv Use of nebivolol for producing anti-atherogenic pharmaceuticals
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ATE437637T1 (de) * 2001-05-02 2009-08-15 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2006025070A2 (en) 2004-07-30 2006-03-09 Torrent Pharmaceuticals Limited Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
NZ560386A (en) * 2005-01-31 2009-12-24 Mylan Lab Inc Pharmaceutical composition comprising hydroxylated nebivolol
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
PL2220030T3 (pl) 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
EP2379710A1 (en) * 2008-12-19 2011-10-26 Schering Corporation Feed supplement for mammalian cell culture and methods of use
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
WO2011150859A1 (en) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Oral meclizine aqueous formulations with taste flavoring agent
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
TWI621434B (zh) * 2014-10-24 2018-04-21 朗齊生物醫學股份有限公司 千憂解藥物應用於癌症治療
HUE058877T2 (hu) 2014-12-16 2022-09-28 Ptc Therapeutics Inc (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
HU226208B1 (en) * 1994-12-28 2008-06-30 Janssen Pharmaceutica Nv Use of nebivolol for producing anti-atherogenic pharmaceuticals

Also Published As

Publication number Publication date
US5874461A (en) 1999-02-23
DK0801564T3 (da) 2002-07-15
WO1996019987A1 (en) 1996-07-04
AU4347796A (en) 1996-07-19
CN1167418C (zh) 2004-09-22
FI972793L (fi) 1997-06-27
EP0801564B1 (en) 2002-03-27
DE69526120D1 (de) 2002-05-02
DE69526120T2 (de) 2002-11-28
NO972980L (no) 1997-06-26
HU226208B1 (en) 2008-06-30
CN1171739A (zh) 1998-01-28
CZ191997A3 (cs) 1999-01-13
MX9704669A (es) 1997-09-30
CA2207333C (en) 2006-10-17
SK282144B6 (sk) 2001-11-06
AU700364B2 (en) 1999-01-07
US6075046A (en) 2000-06-13
PT801564E (pt) 2002-09-30
SI0801564T1 (en) 2002-08-31
ATE214924T1 (de) 2002-04-15
NO972980D0 (no) 1997-06-26
JPH10511655A (ja) 1998-11-10
NO315687B1 (no) 2003-10-13
CA2207333A1 (en) 1996-07-04
EP0801564A1 (en) 1997-10-22
ES2176354T3 (es) 2002-12-01
SK85697A3 (en) 2000-04-10
FI118884B (fi) 2008-04-30
NZ298074A (en) 2001-01-26
HUT77927A (hu) 1998-11-30
CZ287513B6 (en) 2000-12-13
KR100264348B1 (ko) 2000-08-16

Similar Documents

Publication Publication Date Title
NO972980L (no) Anvendelse av nebivolol som et anti-aterogent middel
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BG105275A (en) Tan-1057 derivatives
BG102667A (en) Diosgenine-containing composition
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
AU1278600A (en) Novel therapeutic application of nicergoline
EA199700243A1 (ru) Производное аминотетралина для лечения сердечно-сосудистых заболеваний
NO984651D0 (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
WO1999021538A3 (de) Verwendung von glykosaminoglykanen zur herstellung von pharmazeutischen zubereitungen zur behandlung von mit diabetes assoziierten augenkrankheiten
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
NO984198L (no) FremgangsmÕte for behandling av aggresjon
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118884

Country of ref document: FI

MA Patent expired